Symbol
| S100A1
| contributors: mct - updated : 10-02-2018
|
HGNC name
| S100 calcium binding protein A1
|
HGNC id
| 10486
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --low
|  
|
in cardiomyopathies | constitutional
|  
|  
|  
|  
|
results in pulmonary hypertension (PH), by disruption of its normal capacity to enhance pulmonary endothelial cell function | constitutional
|  
|  
| --low
|  
|
in failing hearts | constitutional
|  
|  
| --low
|  
|
suppresses physiological AP-induced Ca(2+) release flux, resulting in impaired contractile activation and force production in skeletal muscle | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| S100A1 and S100B expression are marker to develop potency assays for cartilage regeneration cell therapies | Therapy target
|
System | Type | Disorder | Pubmed |
neuromuscular | myopathy | | |
therapeutic target for the treatment of both cardiac and skeletal myopathies | cardiovascular | cardiomyopathy | | |
cardiovascular | | | |
ability of exogenously administered S100A1 makes it an attractive therapeutic target in the treatment of Pulmonary hypertension (PMID: 25395393) |
| | |
| ATP synthase activity is reduced in cardiomyocytes from S100a1 knockout mice | |
mice deficient of both the S100a1 and S100b genes displayed normal skeletal growth from embryonic stage to adulthood |
|
S100a1-knock-out mice (KO) exhibited increased right ventricular (RV) weight/body weight ratio and elevated RV pressure in the absence of altered left ventricular filling pressures, accompanied by increase in wall thickness of muscularized pulmonary arteries and a reduction in microvascular perfusion |